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Therapeutical Experience in Classic Kaposi’s Sarcoma
L Brambilla, V Boneschi, S Ferrucci, M Brambati, M Bellinvia and M Scoppio
Institute of Dermatological Sciences - Universita` degli Studi di Milano, Fondazione
IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano
In 28 years’ experience we observed 550 classic Kaposi’s sarcoma patients. Many
of them underwent local and/or systemic chemotherapy. On the basis of such a
large survey we had the opportunity to develop a clinical staging system in order to
decide the therapeutical strategy, useful especially in older and impaired patients.
In initial stages (I and II with slow progression) we prefer clinical observation,
intralesional chemotherapy (vincristine) for isolated nodules, radiotherapy in
selected cases and compression with elastic stockings. In stages II with fast
progression, III and IV, basic therapy is systemic mono- or polychemotherapy, with
compression with elastic stockings as a useful support. As first-line therapy we use:
Vinblastine: induction 4, 6, 8 mg i.v./week, maintenance 10 mg i.v. every 3 weeks
Vinblastine þ Bleomicine 15 mg i.m. every 2 weeks after vinblastine induction.
As second-line therapy:
Vinorelbine: induction: 17.5 mg/m2 every 2 weeks for 5 cycles; maintenance
29 mg/m2 every 3 weeks.
Etoposide 150 mg/die i.v. for 3 consecutive days every 3 weeks.
Gemcitabine 1200 mg/m2 i.v. weekly for 2 weeks followed by a three-weeks
interval
Epirubicine 20 mg i.v. weekly
All these chemotherapies have to be maintained up to the best clinical result
followed by three-consolidation cycles.
Therapeutical news:
Taxole 100 mg i.v. weekly.
Liposomal Doxorubicine 20 mg/m2 every 3 weeks for 6 cycles.
Proteasis inhibitors
Therapy guidelines will be described and discussed presenting our personal
experience.
FC25
Sentinel Node Biopsy in Melanoma Delays Recurrence but does not
Change Melanoma-Related Survival – a Retrospective Analysis of 856
Patients
I Satzger, A Kapp and R Gutzmer
Department of Dermatology and Allergology, Hannover Medical University,
Hannover, Germany
The status of the sentinel node (SLN) is an important parameter to predict the
prognosis of melanoma patients but it is a matter of debate if removal of
micrometastases by SLN biopsy (SLNB) influences the prognosis of melanoma
patients. We sought to investigate the impact of SLNB in melanoma patients with
regard to recurrence free survival, overall survival, and metastatic pathways. 856
melanoma patients with a primary melanoma (tumor thickness 1 mm) and without
clinical evidence of metastases at time of melanoma diagnosis were retrospectively
studied. In 378 patients the melanoma was removed without SLNB from January
1995 until March 2000 (preSLNB-group). In 478 patients the melanoma was
removed with SLNB from April 2000 until December 2004 (SLNB-group).
Otherwise, both groups received identical surgical treatment of the primary
melanoma and initial staging procedures performed by the same team of
physicians. Follow up recommendations were also identical in both groups. Both
groups showed no significant differences with regard to Breslow thickness, Clark
level, ulceration and location of primary melanomas. By Kaplan Meier analyses,
melanoma related overall survival was comparable in both groups. However,
recurrence free survival was increased in preSLNB patients due to significantly
fewer regional lymph node metastases, whereas frequencies of loco-regional
cutaneous and distant metastases were comparable in both groups. We conclude
that SLNB advances the detection of regional lymph node metastases and avoids
therefore nodal recurrences but does not influence metastatic behaviour of
melanoma cells and does not protect patients from melanoma related death
caused by distant metastases.
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Isolated HMB45 or MelanA Positive Cells Are Without Prognostic
Significance in Melanoma Sentinel Lymph Nodes
I Satzger, B Vo¨lker, A Kapp and R Gutzmer
Department of Dermatology and Allergology, Hannover Medical School, Hann-
over, Germany
The detection of micrometastases (defined as groups of malignant cells) in the
sentinel lymph node (SLN) is an important prognostic tool in melanoma. The use of
immunohistochemistry with melanocytic markers such as HMB45 and MelanA
increases the detection rate of micrometastases but there are also cases with
isolated immunohistochemically positive cells (IPC). To determine the prognostic
significance of isolated HMB45 and/or MelanA positive cells in melanoma SLN, we
compared 47 patients with isolated IPC to 308 patients with negative SLN and to
122 patients with micrometastases. By Kaplan Meier analyses, relapse free survival
(RFS) and overall survival (OS) of patients with isolated IPC were similar to SLN
negative patients, whereas patients with micrometastases had a significantly worse
RFS and OS. In the 47 patients with isolated IPC, 5 relapses (10.6 %) and 1
melanoma related death (2.1%) occurred, in the SLN negative patients 31 relapses
(10.1%) and 16 melanoma deaths (5.2%), in the patients with micrometastases 45
relapses (36.9%) and 24 melanoma related deaths (19.7%). Prognosis of patients
with isolated IPC did not correlate with number of cells, type of positive staining
(HMB45, MelanA, or both), presence of cytologic atypias, or tumor penetrative
depth. In conclusion, isolated IPC in melanoma sentinel lymph nodes are without
prognostic significance. Sentinel lymph nodes with this finding should be reported
as negative.
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Lack of Survival Benefit After SLNB: Results of a Monocentric
Retrospective Analysis
U Leiter, K Bohnenberger, M Moehrle and C Garbe
Department of Dermatology, Eberhard-Karls-University, Tu¨bingen, Germany
Backgound: Sentinel lymph node biopsy (SLNB) and following lymph node
dissection (SLND) is commonly performed in the treatment of primary cutaneous
melanoma (CM). The role of SLND in the treatment of CM is still discussed
controversially. Until now no definitive guidelines do exist. Methods: 879 patients
with primary cutaneous melanoma treated in the Department of Dermatology of
the University of Tu¨bingen were analysed using Kaplan Meier analysis and Log
Rank tests. 439 patients treated with SLNB/SLND from 1996 to 2000 were
compared retrospectively to 440 patients with a tumor thickness of 1.00 mm or
more without SLNB (control collective) concerning the metastatic course, disease
free and overall survival. Results In a median follow up time of 50.2 month SLNB
patients showed a significantly lower rate of primary lymph node metastases
(po0.0001) whereas no significant differences were observed for primary
locoregional recurrences (p¼0.59) or distant metastases (p¼ 0.136). Concerning
disease free survival, SLNB/SLND patients showed a longer disease free survival
than patients without SLNB/SLND (p¼0.023), whereas the SLNB had no effects on
the distant metastasis free survival (p¼0.75) or the overall survival (p¼ 0.275).
Conclusion In this analysis SLNB/SLND fits the aim to restrict primary regional
lymph node metastasis in the follow up and seems to have a positive effect on a
prolonged disease free survival. However, no effect on the distant metastases free
survival and the overall survival could be demonstrated.
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Molecular Detection of Melanoma-Associated Markers in Blood: MUC-
18 Is Associated with High Grade Malignancy and Poor Prognosis
MC Rapanotti*, I Ricozziy, G Federici*, L Bianchiy, S Chimentiy, S Bernardini*
*Dipartimento di Medicina Interna e di Laboratorio, yClinica Dermatologica-
Azienda Ospedaliera Universitaria- ROMA ‘‘Tor Vergata’’
Detection of circulating melanoma cells (CMC) in peripheral blood (PB) was first
reported by Hoon D.S. et al (1995), who described the use of a multi-marker RT-
PCR-assay considered to be predictive of early disease recurrence or progression.
Aim: We evaluated the simultaneous expression of some melanoma-associated
mRNAs (MAMs) in PB of 100 patients affected by melanoma. The aim of our study
was to better evaluate the clinical effectiveness of cancer treatment and to detect
‘‘subclinical’’ disease in clinically disease-free patients. Patients and methods: We
analyzed 49 males and 51 females, 91 of them were AJCC stage I-II, 5 AJCC stage III
and 4 AJCC stage IV, all have been submitted to melanoma surgery between 1987
and 2005. Ninety-one of 100 patients were clinically disease-free by conventional
physical examination and imaging, at the time of the analysis. The MAMs were:
tyrosinase (TyrOH), MAGE-3, MART-1, p97 and MUC-18. Results and conclusion:
We documented the presence of at least one MAMs in 23 cases (23%). Our data
showed that patients with AJCC stage III-IV are not associated with a significant
positivity of blood sharing at least 3-4 markers. We didn’t detect any association
with the expression of TyrOH, MART-1, MAGE-3, p97 and disease progression.
MUC-18 is well-known to be a MAM associated with tumor progression. In our
study, MUC-18 is the only marker associated with more advanced disease stage,
both alone and in combination with the other MAMs.
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Hereditary Multiple Cutaneous and Uterine Leiomyomatosis
E Campione*, A Terrinoni$, A Orlandi1, JH Hagman*, L Bianchi* and S Chimenti*
*Department of Dermatology, University of Rome "Tor Vergata", Rome, Italy, $IDI,
IRCSS Biochemistry Laboratory, c/o Department of Experimental Medicine, of
Rome ‘‘Tor Vergata’’, Rome, Italy and 1Department of Pathology, University of
Rome ‘‘Tor Vergata’’, Rome, Italy
Hereditary multiple cutaneous and uterine leiomyomatosis (MCUL) is an autosomal
dominant disease which can be associated with type II papillary renal cancer
(HLRCC). The genetic locus for MCUL and HLRCC was recently mapped to
chromosome 1q42.3-43 and germline mutations in the fumarate hydratase (FH)
gene have been found. FH is an enzyme that catalyzes the conversion of fumarate
to malate in the tricarboxylic acid cycle. The FH gene seems to act as tumor
suppressor since loss of the wild-type allele has been identified in cutaneous,
uterine, and renal tumour of MCUL/HLRCC patients. FH enzymatic activity is
absent in mutated proteins but, since the disorder is transmitted with heterozygous
modality, patients show a reduced activity near to 50%. We report a study on an
Italian family with history of cutaneous leiomyomas and uterine fibroids. The first
patient is a 35 year-old man affected by multiple brownish nodules localized on the
abdomen with a past medical history of surgical removed cutaneous leiomyomas
15 years before. The past medical history of the patient’s mother revealed a surgical
hysterectomy for multiple uterine fibroids. Moreover, she also presented multiple
brownish nodules on her trunk. The histopathology of the skin lesions confirmed, in
both patients, the diagnosis of MCUL. Molecular analysis on FH gene mutations is
also presented.
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Redness, a Possible Signpost for Malignant Melanoma
J Mashiah1, Y Wohl1, Y Barnea2, S Schneebaum3, A Gat4, F Misonzhnik-Bedny4
and S Brenner1
Departments of 1Dermatology, 2Plastic Surgery, 3General Surgery A and
4Pathology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine,
Tel Aviv University, Israel
Objective: To confirm the existence and determine the mechanism of a previously
described observation of erythematous macular eruption in melanoma patients.
Materials: The first study consisted of 3 groups whose clinical parameters were
monitored for 12 months: 14 randomly selected melanoma patients; 15 patients
with basal cell carcinoma, 10 patients with squamous cell carcinoma, and 10
patients with Bowen’s disease; and 30 healthy individuals. In the second study
biopsy specimens from 13 patients with melanoma, 6 with erythematous eruptions
and 7 without, were studied by immunohistochemistry for the expression of
vascular endothelial growth factor (VEGF) and platelet growth factor (PDGF).
Results: In the first study 8 out of 14 (57%) melanoma patients exhibited an
erythematous macular rash adjacent to and in the general vicinity of the primary
tumor. Neither of the other two groups displayed such a rash. In the second study
VEGF was positive in 3 of the 6 (50%) melanoma patients with redness and in 4 of
the 7 (57%) melanoma patients without redness. PDGF was positive in all 6 (100%)
melanoma patients with redness and in 4 of the 7 (57%) melanoma patients without
redness. Conclusion: Melanoma development and progression is accompanied in
some patients by an erythematous rash. PDGF may play a role in the pathogenesis
of the redness by affecting the vasculature function rather than abundance. The
significance of this observation for detection, treatment, and prognosis of malignant
melanoma will be discussed.
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Metastatic Subcutaneous Liposarcoma
M Carrera, P Piemonte, P Di Russo, M Pozzi and P Frascione
Dermatology Division Regina Elena Institute-Rome, Rome, Italy
We present a case of 51-year-old patient, admitted to our department for the
complaint of a firm, red-brownish, partially ulcerated claque on the left gluteal
region. The lesion measured about 5 cm in diameter. In 2002 the patient had
undergone surgical excision of a subcutaneous liposarcoma on the left knee and
had then received postoperative radiation. Besides malignant fibrous histiocytoma,
liposarcoma is the most common malignancy arising from soft tissues in adults. It
represent 20% of all mesenchymal tumors. It is usually located on the lower
extremities and it is mostly intramuscular whereas the subcutaneous forms are quite
rare. In 30% of the cases liposarcoma disseminates to other organs and mortality is
about 40%. Recurrence and metastatic rates are very different, according to the
various subtypes of liposarcoma. The World Health Organization has classified
liposarcoma in five histologic categories: well differentiated, mixoid, round cell,
pleomorphic and dedifferentiated. The better prognosis is associated to well-
differentiated and mixoid subtypes. Primitive subcutaneous liposarcoma is very
rare, mixoid and well-differentiated liposarcomas are the most common subtypes.
www.jidonline.org S31
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Multimarker Real-Time RT-PCR for Quantitative Detection of Melano-
ma Associated Antigens, a New Approach
P Arenberger, M Arenbergerova, S Gkalpakiotis, J Lippert and M Kremen
Department of Dermatology, Charles University 3rd Medical Faculty, Prague,
Czech Republic
Interferon alpha is a standard treatment in patients with malignant melanoma
belonging to stage II and III. However, it is essential to be able to detect the
therapeutic response of adjuvant immunotherapy and to investigate if the disease is
showing regression or progression in clinically tumor-free patients. The best
candidate for such examination seems to be the quantitative detection of tumor
associated antigens. In the past, different authors discussed the relevance of such
detection due to the result inconsistency. However, the main problem was a
methodological difference among various studies. The majority of the previous
studies has been carried out with a single marker, detected by conventional or
semiquantitative RT-PCR. In our study, we introduced a quantitative multimarker
real-time RT-PCR. This method detects the expression of tyrosinase, MART-1, MIA,
MAGE-3 and gp 100 genes exhibiting high specificity for melanoma cells. Fifty
melanoma patients at stage II and III were regularly examined within one year. In
our preliminary results, down-regulation of different markers after the onset of the
immunotherapy with interferon-alpha was observed. Furthermore, a strong
correlation between the up-regulation of different melanoma–associated marker
expression level and development of distant metastases was seen. The best
candidate for this purpose seems to be MAGE-3 which became positive in 85% of
examined patients developing distant metastasis. The results provide us with
information on the frequency of melanoma-associated gene transcripts and help us
to determine which patients are in a risk of developing distant metastases and how
we should proceed with the immunotherapy. The final aim of our study is the
routine usage of this method for rapid screening in risk patients. The work was
supported by the MOH IGA 1A 8243-3 Grant.
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Giant Pilomatricoma
GP Lozzi, HP Soyer*, J Fruehauf*, H Kerl* and K Peris
Department of Dermatology, University of L’Aquila, L’Aquila, Italy and *Depart-
ment of Dermatology, Medical University of Graz, Graz, Austria
Pilomatricoma is a benign skin neoplasm of hair matrix origin that may occur at any
age although it is most common in childhood, adolescence and in adults over 60
years of age. Clinically, pilomatricoma typically presents as a solitary, asympto-
matic, firm, skin-colored to faint blue/red nodule located on the head and neck.
The average size is 1 cm and it very rarely exceeds 3 cm in diameter. Uncommon
clinico-pathologic variants of pilomatricoma such as giant, bullous-like, aneto-
dermic, exophytic, perforating/ulcerated and lymphangiectatic lesions have been
rarely described. We report a 52-year-old man who was examined for an ulcerated,
reddish nodule measuring 11 x 6 x 5.5 cm, located on the left clavicular region. The
lesion had been present for approximately 7 years; it had rapidly increased in size
and ulcerated during the last 2 months. The patient complained occasional burning
and pain. Clinical differential diagnoses included cutaneous lymphoma, sarcoma,
squamous cell carcinoma and cutaneous metastasis. Histopathologic examination
revealed a circumscribed large tumor involving the whole dermis and the subcutis,
composed of partially confluent foci of aggregations of matrical cells admixed with
eosinophilic cornified material containing shadows cells. In addition, multi-
nucleated giant cells, areas of calcification and metaplastic ossification, edema and
hemorrhage were also observed. Based on the clinico-pathologic features the
diagnosis of giant pilomatricoma was made. In conclusion, giant pilomatricoma
can be included in the spectrum of benign giant adnexal neoplasms.
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Cutaneous Photochemoprotection With Topical Application of Low
Dose Green Tea Extract (OM24s) in Humans – a Placebo-Controlled
Trial
CD Mnich, KS Hoek, M Urosevic, A Farkas, C Dudli, E Laine, HE Holzgang-
Schneiter* and R Dummer
Clinic of Dermatology, University Hospital Zurich, Zurich, Switzerland and
*Omnimedica AG, Schlieren, Switzerland
Background: Preclinically, green tea extracts (GTEs) have shown reduction of UVB-
induced (i) erythema, (ii) DNA damage, (iii) formation of radical oxygen species
and (iv) upregulation of numerous factors related to apoptosis, inflammation,
differentiation and carcinogenesis. In humans, topical GTEs have only been tested
in limited studies, with very high concentrations and over short periods of time.
Here, the utility of topical GTEs as everyday photochemopreventive agents was
tested. Probands and Methods: 18 Probands applied over 34 days on UV-protected
skin verum (¼ W/O cream with 0.4% GTE, OM24s) and placebo. 24 h after
irradiation with 100mJ/cm2 UVB, biopsies were taken on day 6 and 34; (A) non-
irradiated; (B) placeboþUVB; (C) GTEþUVB. On paraffin sections, thymidine
dimers, p53, and apoptosis (sunburn cells and TUNEL assay) were histochemically
assessed. Preliminary results: Tolerability was excellent. Comparing biopsy C with
B, p53- positive keratinocytes were reduced in C, by 31.9% (p¼0.002) on day 6
and by 36.3% (p¼ 0.001) on day 34. As was apoptosis [TUNEL-Assay, 66.3%
reduction (p¼0.027) on day 6; and 38.5% reduction (p¼ 0.097) on day 34;
sunburn cells, 38.9% reduction (p¼ 0.02) on day 6]. Thymidine dimer-positive
keratinocytes and erythema response were unchanged between biopsies C and B.
Conclusions: Already at low, cosmetically usable, non-erythema-reducing con-
centrations (0.4%), topically applied GTE (OM24s) significantly reduces UVB-
mediated induction of p53 and apoptosis without tachyphylaxis over five weeks,
suggesting GTEs as suitable everyday photochemopreventive agents.
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Clinical Benefits of Imiquimod 5% Cream Applied Once Daily 3 Days
per Week for the Treatment of Actinic Keratoses in Immunosuppressed
Organ Transplant Recipients
C Ulrich1, J Bichel2, S Euvrard3, B Guidi4, C Proby5, W Sterry1 and E Stockfleth1
1Department of Dermatology, Charite´ Berlin, Germany, 23 M Pharmaceuticals,
Neuss, Germany, 3Department of Dermatology, Edouard Herriot Hospital, Lyon,
France, 4Clinica Dermatologica dell’Universita Cattolica del Sacro Cuore, Roma,
Italy and 5Centre for Cutaneous Research, Bart’s and the London Queen Mary’s
School of Medicine and Dentistry, University of London, London, United Kingdom
Introduction: Non-melanoma skin cancer represents a significant cause of
morbidity in organ transplant patients. In grafted patients the relative risk of
invasive squamous cell carcinoma and actinic keratoses (AK) is up to 250 times
higher compared to non-immunocompromised patients. Topically applied,
imiquimod 5% cream induces local interferon-alpha, interleukin-12 and tumor
necrosis factor alpha. Imiquimod has the potential to be an effective option for the
treatment of AK in organ transplant recipients. Methods: A randomized, double-
blind study evaluated 43 solid organ transplant recipients with multiple AKs (4 to
10 lesions). The patients applied imiquimod or vehicle cream to AK lesions in a
100 cm2 area once daily 3 times a week for a period of 16 weeks. This study
compared imiquimod 5% cream and vehicle cream with respect to graft-safety and
efficacy (complete and partial clearance rates). A posttreatment biopsy of a marker
lesion was performed at the end of study. Results: Of the subjects randomized to
imiquimod, overall clinical/histological clearance rate was 62.1% (18/29); and
0.0% (0/14) for vehicle subjects. No graft rejections or trends for a deterioration of
the graft function were detected. Local skin reactions were well tolerated.
Preliminary Conclusion: The results of this study demonstrated that topical
imiquimod provides a clear medical benefit in the treatment for multiple AK
lesions located in large treatment fields in high risk solid-organ transplant patients.
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